Exelon
Exelon is an originator product from Novartis Pharma Schweiz AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 40.80 to CHF 112.25 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Novartis Pharma Schweiz AG
- ATC code
- N06DA03
- IT group
- 01.99 Varia
- Active substances
- Rivastigminum
- Preparation type
- Originator product
- On the SL since
- 15/03/1997
- Last price change
- 01/07/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Kaps 1.5 mg | 28 Stk | CHF 22.42 | CHF 40.80 | 15/03/1997 | B | 7680542750804 |
| Kaps 1.5 mg | 56 Stk | CHF 40.18 | CHF 60.10 | 15/03/1997 | B | 7680542750996 |
| Kaps 1.5 mg | 112 Stk | CHF 88.12 | CHF 112.25 | 15/03/1997 | B | 7680542751023 |
| Kaps 3 mg | 28 Stk | CHF 22.42 | CHF 40.80 | 15/03/1997 | B | 7680542751108 |
| Kaps 3 mg | 56 Stk | CHF 40.18 | CHF 60.10 | 15/03/1997 | B | 7680542751290 |
| Kaps 3 mg | 112 Stk | CHF 88.12 | CHF 112.25 | 15/03/1997 | B | 7680542751375 |
| Kaps 4.5 mg | 28 Stk | CHF 22.42 | CHF 40.80 | 15/03/1997 | B | 7680542751450 |
| Kaps 4.5 mg | 112 Stk | CHF 88.12 | CHF 112.25 | 15/03/1997 | B | 7680542751610 |
| Kaps 6 mg | 28 Stk | CHF 22.42 | CHF 40.80 | 15/03/1997 | B | 7680542751818 |
| Kaps 6 mg | 112 Stk | CHF 88.12 | CHF 112.25 | 15/03/1997 | B | 7680542752181 |
| Lös 2 mg/ml | 120 ml | CHF 62.35 | CHF 84.25 | 01/01/2000 | B | 7680550510025 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Zu Therapiebeginn und regelmässig im Verlauf der Therapie (alle 6 Monate) ist jeweils im Rahmen der klinischen Gesamtbeurteilung (Alltagsfunktion, Verhaltensauffälligkeiten, Kognition) eine Beurteilung der Kognition mittels kognitivem Screening vorzunehmen: Durchführung eines Minimentaltests (mini mental status examination (MMSE), ggf. Umrechnung Montreal Cognitive Assessment (MoCA). Im Stadium schwerer Demenz oder wenn die MMSE-Werte unter 10 liegen, ist die Behandlung zu beenden. Die Behandlung darf nur mit einem Präparat zur Behandlung der Demenz vom Typ der Alzheimer-Krankheit oder assoziiert mit der Parkinson Krankheit durchgeführt werden, eine Kombinationsbehandlung wird nicht vergütet.
More preparations in this group
FAQ
Is Exelon covered by Swiss health insurance?
Yes, but only under conditions. Exelon is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Exelon cost in Switzerland?
The public price is the maximum price set by the FOPH and for Exelon ranges from CHF 40.80 to CHF 112.25 per pack. The ex-factory price ranges from CHF 22.42 to CHF 88.12. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages